Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
作者： Rong Deng , Feng Jin , Saileta Prabhu , Suhasini Iyer
DOI: 10.1517/17425255.2012.643868
关键词:
摘要: … knowledge of monoclonal antibodies. Specifically, the authors discuss monoclonal antibodies with respect to … Expert opinion: Monoclonal antibodies have complex pharmacokinetic and …
informahealthcare.com参考文章(108)
Donald E. Mager, William J. Jusko, General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 28, pp. 507- 532 ,(2001) , 10.1023/A:1014414520282
Sergei M. Danilov, Vitaly D. Gavrilyuk, Folker E. Franke, Katarina Pauls, David W. Harshaw, Timothy D. McDonald, David J. Miletich, Vladimir R. Muzykantov, Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. American Journal of Physiology-lung Cellular and Molecular Physiology. ,vol. 280, ,(2001) , 10.1152/AJPLUNG.2001.280.6.L1335
Diane R Mould, Kevin R D Sweeney, The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development Current Opinion in Drug Discovery & Development. ,vol. 10, pp. 84- 96 ,(2007)
Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson, Zephania W. Kwong, Jihong Yang, Xiangdan Wang, Zhenling Yao, Alavattam Sreedhara, Tony Cano, Devin B. Tesar, Ihsan Nijem, David E. Allison, Pin Yee Wong, Yung-Hsiang Kao, Cynthia Quan, Amita Joshi, Reed J. Harris, Paul Motchnik, Charge variants in IgG1 mAbs. ,vol. 2, pp. 613- 624 ,(2010) , 10.4161/MABS.2.6.13333
F. W. R. BRAMBELL, W. A. HEMMINGS, I. G. MORRIS, A Theoretical Model of γ-Globulin Catabolism Nature. ,vol. 203, pp. 1352- 1355 ,(1964) , 10.1038/2031352A0
Yik Andy Yeung, Maya K. Leabman, Jonathan S. Marvin, Julia Qiu, Camellia W. Adams, Samantha Lien, Melissa A. Starovasnik, Henry B. Lowman, Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. Journal of Immunology. ,vol. 182, pp. 7663- 7671 ,(2009) , 10.4049/JIMMUNOL.0804182
Rong Deng, Suhasini Iyer, Frank-Peter Theil, Deborah L. Mortensen, Paul J. Fielder, Saileta Prabhu, Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? mAbs. ,vol. 3, pp. 61- 66 ,(2011) , 10.4161/MABS.3.1.13799
Derry C. Roopenian, Gregory J. Christianson, Thomas J. Sproule, Aaron C. Brown, Shreeram Akilesh, Nadja Jung, Stefka Petkova, Lia Avanessian, Eun Young Choi, Daniel J. Shaffer, Peter A. Eden, Clark L. Anderson, The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs Journal of Immunology. ,vol. 170, pp. 3528- 3533 ,(2003) , 10.4049/JIMMUNOL.170.7.3528
Joachim Kempeni, Piet L. C. M. Van Riel, Manfred Schattenkirchner, Rolf Rau, Alfons Den Broeder, Oliver Sander, Helmut Fenner, Leo B. A. Van De Putte, Raja Velagapudi, Yvonne Bankmann, Christina Binder, Hartmut Kupper, A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. The Journal of Rheumatology. ,vol. 29, pp. 2288- 2298 ,(2002)
L. J. Benincosa, E. Minthorn, L. A. P. Tobia, T. K. Hart, C. B. Davis, C. S. Hottenstein, P. Zia-Amirhosseini, Pharmacokinetics and Pharmacodynamics of SB-240563, a Humanized Monoclonal Antibody Directed to Human Interleukin-5, in Monkeys Journal of Pharmacology and Experimental Therapeutics. ,vol. 291, pp. 1060- 1067 ,(1999)